BioNTech (NASDAQ:BNTX)‘s stock had its “sell” rating reiterated by investment analysts at Redburn Partners in a research report issued on Wednesday, Benzinga reports.
Other equities research analysts have also issued research reports about the stock. Zacks Investment Research raised shares of BioNTech from a “hold” rating to a “strong-buy” rating and set a $193.00 price objective on the stock in a report on Friday, May 7th. JPMorgan Chase & Co. set a $104.00 target price on shares of BioNTech and gave the company a “neutral” rating in a research report on Tuesday, April 6th. The Goldman Sachs Group started coverage on shares of BioNTech in a research report on Tuesday, May 18th. They set a “neutral” rating and a $173.00 target price on the stock. Bryan, Garnier & Co restated a “neutral” rating and set a $206.00 target price (up from $135.00) on shares of BioNTech in a research report on Monday, May 17th. Finally, Berenberg Bank set a $130.00 target price on shares of BioNTech and gave the company a “buy” rating in a research report on Tuesday, April 6th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $151.30.
BNTX opened at $218.17 on Wednesday. The stock has a 50-day moving average price of $185.52. The company has a current ratio of 2.70, a quick ratio of 2.58 and a debt-to-equity ratio of 0.09. BioNTech has a twelve month low of $49.09 and a twelve month high of $252.78. The company has a market cap of $52.69 billion, a price-to-earnings ratio of 38.21 and a beta of -1.58.
BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Sunday, May 9th. The company reported $4.39 EPS for the quarter, topping analysts’ consensus estimates of $3.09 by $1.30. BioNTech had a net margin of 48.40% and a return on equity of 91.61%. The firm had revenue of $2.05 billion for the quarter, compared to analyst estimates of $1.40 billion. The business’s quarterly revenue was up 7294.9% on a year-over-year basis. As a group, sell-side analysts predict that BioNTech will post 30.71 EPS for the current fiscal year.
Large investors have recently added to or reduced their stakes in the stock. Sterling Investment Advisors Ltd. acquired a new stake in shares of BioNTech during the first quarter worth $27,000. John W. Brooker & Co. CPAs acquired a new stake in shares of BioNTech during the first quarter worth $33,000. Captrust Financial Advisors lifted its holdings in shares of BioNTech by 433.3% during the fourth quarter. Captrust Financial Advisors now owns 400 shares of the company’s stock worth $33,000 after buying an additional 325 shares in the last quarter. Parallel Advisors LLC raised its stake in BioNTech by 550.0% in the first quarter. Parallel Advisors LLC now owns 325 shares of the company’s stock valued at $35,000 after purchasing an additional 275 shares in the last quarter. Finally, US Bancorp DE acquired a new position in BioNTech in the fourth quarter valued at about $46,000. 12.40% of the stock is owned by institutional investors and hedge funds.
BioNTech Company Profile
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors.
Read More: Trading Penny Stocks